# Junta clínica — PT-pseudo_1185f6a68df0 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_1185f6a68df0",
  "pid": "PT-pseudo_1185f6a68df0",
  "task": 1,
  "psa": 7.0,
  "age": 63,
  "months": 2,
  "pirads": "5",
  "psad": 0.329,
  "psav": 1.09,
  "psap": 5.5,
  "vol": 21.27,
  "dre": "Normal",
  "bx": "None",
  "cspca": 0.8321669,
  "medhx": "Atrial fibrillation",
  "meds": "apixaban, metoprolol",
  "notes": "PSA 7 ng/mL. PI-RADS 5. PSAD 0.33. Prostate volume 21 mL. csPCa 0.83.",
  "pmhx": [
    "Atrial fibrillation"
  ],
  "allergies": [],
  "vitals": {
    "weight": "101 kg",
    "height": "179 cm",
    "bmi": "31.5",
    "bp": "100/66 mmHg",
    "hr": "72 bpm",
    "smoking": "Ex-smoker (22 pack-yr, quit 2021)",
    "last_dental": "6 mo ago",
    "flu_vax": "Sep 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "22 Feb 2025",
  "enc_ref": "Dr. P. van Dijk (GP)",
  "enc_type": "Follow-up - PSA + MRI",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Escalating prostate-specific antigen measurements across a two-year span prompted a recent multiparametric magnetic resonance imaging study."
    },
    {
      "s": "History",
      "t": "At sixty-three years of age, this retired mechanical engineer first entered clinical evaluation in early 2023 due to a PSA elevation, which has since steadily ascended to 7.0 ng/mL. His urological documentation indicates a prior biopsy bucket of None. Lower urinary tract complaints remain minimal, characterized by slight hesitancy and a modest increase in nocturia, yielding an IPSS score of 7. He explicitly denies hematuria or pelvic discomfort. Physical activity persists through cycling roughly 30 kilometres three times weekly, although advancing joint stiffness necessitates a walking frame for extended distances. He shares his home with his wife, while their grown daughter handles administrative correspondence. His clinical background includes atrial fibrillation, managed with apixaban and metoprolol. A substantial smoking history of 22 pack-years was successfully abandoned in 2021. Aside from receiving a standard influenza vaccination last week and maintaining stable blood pressure readings, he reports feeling generally well, with no complaints of unexplained fatigue or weight reduction."
    },
    {
      "s": "Physical examination",
      "t": "DRE — texture: smooth and uniformly firm; mobility: unrestricted; asymmetry: absent. General inspection reveals a well-nourished individual in no acute distress. Vital signs demonstrate a regular heart rate of 72 beats per minute alongside a blood pressure of 100/66 mmHg. Peripheral pulses remain palpable, and there is no clinical evidence of peripheral oedema or lymphadenopathy."
    }
  ],
  "occupation": "retired mechanical engineer",
  "marital": "Married",
  "living": "Lives with partner",
  "next_of_kin": "Adult daughter (primary contact)",
  "recent_other": [
    "GP practice nurse — flu vaccination"
  ],
  "alcohol": "5 units / week",
  "exercise": "Cycling 3x/week, ~30 km",
  "ipss": "IPSS score: 7/35 (mild LUTS)",
  "admin": "Mobility limitation (frame); ground-floor consult room preferred.",
  "mri_hospital": "Maastricht UMC+",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_1185f6a68df0
Task: 1

Encounter: Urology - outpatient on 22 Feb 2025.
Referrer: Dr. P. van Dijk (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 63-year-old male
  - PSA: 7.0 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.329 ng/mL²
  - PSA velocity: 1.09 ng/mL/yr
  - Prior PSA: 5.5 ng/mL
  - Prostate volume: 21.27 mL
  - Months since last PSA: 2
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.8321669 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Atrial fibrillation
  - Problem list / PMHx: Atrial fibrillation
  - Current medication: apixaban, metoprolol
  - Allergies: NKA
  - Additional notes: PSA 7 ng/mL. PI-RADS 5. PSAD 0.33. Prostate volume 21 mL. csPCa 0.83.

Vitals: weight 101 kg, height 179 cm, BMI 31.5, BP 100/66 mmHg, HR 72 bpm. Smoking: Ex-smoker (22 pack-yr, quit 2021).

Chief complaint: Escalating prostate-specific antigen measurements across a two-year span prompted a recent multiparametric magnetic resonance imaging study.

History: At sixty-three years of age, this retired mechanical engineer first entered clinical evaluation in early 2023 due to a PSA elevation, which has since steadily ascended to 7.0 ng/mL. His urological documentation indicates a prior biopsy bucket of None. Lower urinary tract complaints remain minimal, characterized by slight hesitancy and a modest increase in nocturia, yielding an IPSS score of 7. He explicitly denies hematuria or pelvic discomfort. Physical activity persists through cycling roughly 30 kilometres three times weekly, although advancing joint stiffness necessitates a walking frame for extended distances. He shares his home with his wife, while their grown daughter handles administrative correspondence. His clinical background includes atrial fibrillation, managed with apixaban and metoprolol. A substantial smoking history of 22 pack-years was successfully abandoned in 2021. Aside from receiving a standard influenza vaccination last week and maintaining stable blood pressure readings, he reports feeling generally well, with no complaints of unexplained fatigue or weight reduction.

Physical examination: DRE — texture: smooth and uniformly firm; mobility: unrestricted; asymmetry: absent. General inspection reveals a well-nourished individual in no acute distress. Vital signs demonstrate a regular heart rate of 72 beats per minute alongside a blood pressure of 100/66 mmHg. Peripheral pulses remain palpable, and there is no clinical evidence of peripheral oedema or lymphadenopathy.

Patient info: retired mechanical engineer; Married; Lives with partner.
Next of kin: Adult daughter (primary contact).

Lifestyle: alcohol 5 units / week; exercise Cycling 3x/week, ~30 km; IPSS score: 7/35 (mild LUTS).

Recent other appointments: GP practice nurse — flu vaccination.
Admin: Mobility limitation (frame); ground-floor consult room preferred.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-CLASSIFIER

*statistical classifier; suggests a starting point, decides nothing* · vuelta 1

A classifier trained only to open the discussion, not to close it. Here is its bid.

SUGGESTION: BIOPSY   p(biopsy) = 0.92
  uncertainty  +/- 0.04 (95% CI 0.84-0.99); among patients it cannot tell apart the outcome was 0.41 of 1.00 mixed
  confidence   HIGH — in this tier it was right in every one of the 28 labelled cases it covered

It read ONLY these variables: PI-RADS, prior biopsy status, PSA, age, PSA density, DRE, prostate volume, number of problems on the list. Nothing else — not the mpMRI prose, not the PSA
trajectory, not the previous notes, not this patient's management plan. Values it could not
read for this patient: none.
Out-of-fold over 91 labelled cases (5x5 StratifiedKFold, out-of-fold): accuracy 0.714 against a
majority-class baseline of 0.615, AUC 0.789, F1(yes) 0.78.

The final call is the senior urologist's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: never biopsied. My criterion answers BIOPSY.

The criterion: sample when the mpMRI shows a PI-RADS 3 or higher lesion; defer at PI-RADS 1-2. In the labelled series this criterion matched the reading urologist in 24 of 24 cases in exactly this situation.

Like the classifier, I have read ONLY the visible panel — not the mpMRI prose, the PSA
trajectory, the previous notes or the laboratory panel. Departing from me needs a specific
finding from a document somebody actually opened, named out loud. Not a restatement of the
panel numbers I already used.

## Intervención 5 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The guideline suggests that a PI-RADS score of 3 or higher is used to trigger a biopsy. The retrieved text states: "a PI-RADS threshold of \u2265 3 is used to trigger biopsy [135, 226, 264, 375], at the cost of missing a small number of mainly ISUP GG 2 cancers, especially in biopsy-naive patients or in highly selected populations with high prevalence of csPCa (in which the MRI NPV decreases) [372, 472]."

WHAT THE CLASSIFIER'S BID DOES NOT SETTLE
The classifier's suggestion of biopsy is not sufficiently grounded in the guideline because it fails to account for the specific context of the PI-RADS score threshold. The guideline sets a clear threshold of PI-RADS $\ge 3$ to trigger biopsy, which is a variable the classifier's model, which only read the visible panel, could not fully represent.

WHAT WE STILL NEED
The mpMRI prose - the mpMRI prose does not compare against an earlier study; the guideline does not specify what to do if the lesion is unchanged, but it implies that a stable MRI (PRECISE 1-3) does not make repeat biopsy superfluous.
The prior biopsy status - the patient has "None," which is a critical factor as the guideline notes that the threshold applies especially to "biopsy-naive patients."
The csPCa probability - the guideline notes that the threshold is applied in "highly selected populations with high prevalence of csPCa (in which the MRI NPV decreases)."

## Intervención 6 — MODERATOR

*chairs the discussion; sets the verification plan and the open questions* · vuelta 1

This case hinges on whether the PI-RADS 5 score, combined with the patient being biopsy-naive, warrants a biopsy according to the EAU guidelines.

Before anyone argues, this is what I want established, and by whom.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Determine if the mpMRI prose compares the current lesion against an earlier study.
  psa_trend (get_psa_trend) -> Determine the serial PSA values to assess the PSA trajectory.
  previous_notes (get_previous_notes) -> Determine the management context, specifically the prior biopsy status.

OPEN QUESTIONS for this conference — these are what the decision hangs on, and I expect them answered by name, not in general terms:
  Q1. What does the mpMRI prose state regarding whether the lesion is compared against an earlier study?

On the plan itself: laboratory_results dropped: requested without naming one of the three questions that justify it (free-PSA fraction, infection or prostatitis explaining the PSA, fitness for the procedure). The DRE and the headline PSA are already on the panel. 'search_guidelines' is not a document that exists in this task; dropped. Dropped 1 question(s) that asked for a value already printed on the panel: "What is the csPCa probability, and how does this factor influence the decision given the PI-RADS 5 score?" — the room can read it off intervention 1.

## Intervención 7 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
The mpMRI prose states that the lesion is a focal hypointense area measuring roughly 12 x 9 mm within the left peripheral zone at the mid-gland level, and it does not explicitly compare this finding against an earlier study.

psa_trend
The serial PSA values are: "Mar 2023, 1.3", "Feb 2024, 3.0", and "Feb 2025, 7.0".

previous_notes
The management context, specifically the prior biopsy status, indicates that the urological documentation shows a prior biopsy bucket of "None".

WHAT I DID NOT OPEN
I did not open laboratory_results because the moderator did not ask for a specific question justifying it, and the DRE and headline PSA were already on the panel.

WHAT THIS SUPPORTS
FOR sampling this patient now
The mpMRI prose does not compare the current lesion against an earlier study, which is a point of uncertainty.
The previous_notes indicate the patient has a prior biopsy status of "None," which is a critical factor for biopsy-naive patients.

AGAINST sampling this patient now
nothing

WHERE THIS LEANS
The PI-RADS 5 score combined with the patient being biopsy-naive strongly supports the suggestion of biopsy, aligning with the cohort criterion.
LEAN: biopsy

## Intervención 8 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The registrar answered Q1 by stating that the mpMRI prose does not explicitly compare the current finding against an earlier study.

ALIGNMENT WITH THE CLASSIFIER
The retrieved evidence aligns with the EXPERT-COHORT's leaning towards biopsy, as the registrar noted the lack of comparison in the mpMRI prose and the prior biopsy status was "None," which supports the cohort criterion.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What does the mpMRI prose state regarding whether the lesion is compared against an earlier study? This is answered by the registrar, who stated that the mpMRI prose does not explicitly compare the current finding against an earlier study.

WHAT CARRIES WEIGHT, AND WHY
The two most relevant variables are the PI-RADS 5 score, which indicates high suspicion, and the prior biopsy status of "None," which makes the patient biopsy-naive, both of which strongly support the suggestion of biopsy according to the cohort criterion. The guideline's focus on biopsy-naive patients is highly relevant here. The guideline does not explicitly support deferral when PI-RADS is 5 in a biopsy-naive patient.

MY SUGGESTION TO THE CHAIR
I suggest proceeding with a biopsy, as the combination of a PI-RADS 5 score and being biopsy-naive strongly supports the cohort criterion, despite the guideline's caveats regarding csPCa probability.

VERDICT: ready | SUGGEST: biopsy | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 9 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: clear)

The PI-RADS 5 score is decisive, and the patient is biopsy-naive, which strongly supports the cohort criterion for proceeding with a biopsy. This decision is further supported by the PSA trajectory and the elevated PSA density (0.329 ng/mL²), which together indicate a high likelihood of clinically significant prostate cancer. The lack of comparison in the MRI prose and the prior biopsy status of 'None' were key factors that led to this conclusion.

What carried weight: bx=noted, age=important, psa=important, vol=noted, psad=important, cspca=noted, pirads=decisive, comorbidity=noted
Documents this conference opened: radiology_report, psa_trend, previous_notes
